Envista (NYSE:NVST) Downgraded by Wall Street Zen to “Buy”

Wall Street Zen cut shares of Envista (NYSE:NVST) from a strong-buy rating to a buy rating in a research note released on Saturday morning,Wall Street Zen reports.

Several other equities research analysts also recently weighed in on the company. Morgan Stanley set a $23.00 price target on Envista in a report on Thursday, August 6th. Zacks Research raised shares of Envista from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 7th. Piper Sandler reiterated a “neutral” rating and issued a $28.00 target price (up from $26.00) on shares of Envista in a research note on Thursday, August 6th. Robert W. Baird set a $34.00 target price on shares of Envista in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. raised shares of Envista from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $29.00 to $32.00 in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, Envista presently has an average rating of “Moderate Buy” and an average target price of $29.71.

Envista Stock Performance

Shares of NVST opened at $27.12 on Friday. The company has a current ratio of 2.43, a quick ratio of 2.07 and a debt-to-equity ratio of 0.47. The firm has a market cap of $4.36 billion, a PE ratio of 46.76, a P/E/G ratio of 1.30 and a beta of 0.86. Envista has a 12 month low of $18.77 and a 12 month high of $30.42. The stock has a fifty day moving average price of $27.23 and a 200-day moving average price of $26.29.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.07. Envista had a return on equity of 7.88% and a net margin of 3.33%.The firm had revenue of $730.50 million for the quarter, compared to the consensus estimate of $716.11 million. During the same period in the previous year, the business earned $0.26 EPS. The firm’s revenue for the quarter was up 7.1% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. Equities research analysts predict that Envista will post 1.53 earnings per share for the current fiscal year.

Insider Transactions at Envista

In other Envista news, SVP Mischa Reis sold 8,000 shares of the company’s stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total value of $220,000.00. Following the sale, the senior vice president directly owned 27,321 shares of the company’s stock, valued at approximately $751,327.50. This represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Envista

A number of institutional investors have recently modified their holdings of NVST. GSA Capital Partners LLP acquired a new position in Envista in the second quarter valued at approximately $2,039,000. Pzena Investment Management LLC purchased a new stake in Envista in the 2nd quarter worth approximately $30,494,000. SummitTX Capital L.P. acquired a new stake in shares of Envista during the 1st quarter worth approximately $4,268,000. Dimensional Fund Advisors LP grew its stake in shares of Envista by 1.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock worth $248,130,000 after purchasing an additional 152,488 shares during the period. Finally, Intech Investment Management LLC purchased a new position in shares of Envista during the 4th quarter valued at approximately $2,501,000.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.